BDRX Overview

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

Wall Street analysts forecast BDRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDRX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Biodexa Pharmaceuticals PLC revenue for the last quarter amounts to NaN USD, decreased

Biodexa Pharmaceuticals PLC. EPS for the last quarter amounts to USD, decreased

Biodexa Pharmaceuticals PLC (BDRX) has 16 emplpoyees as of April 21 2026.

Today BDRX has the market capitalization of 2.81M USD.